Kay Ka-Wai Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2197426/publications.pdf

Version: 2024-02-01

34	966	430874	454955
papers	citations	18 h-index	30 g-index

36	36	36	1849
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Expanding the clinical and molecular spectrum of pituitary blastoma. Acta Neuropathologica, 2022, 143, 415-417.	7.7	2
2	Molecular landscape of IDHâ€wildâ€type, H3â€wildâ€type glioblastomas of adolescents and young adults. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	0
3	Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. Laboratory Investigation, 2022, 102, 731-740.	3.7	5
4	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. Frontiers in Oncology, 2022, 12, 839302.	2.8	3
5	RARE-06. Expanding the clinical and molecular spectrum of pituitary blastoma. Neuro-Oncology, 2022, 24, i10-i10.	1.2	0
6	Lowâ€grade BRAF V600E mutant oligodendrogliomaâ€like tumors of children may show EGFR and MET amplification. Brain Pathology, 2021, 31, 211-214.	4.1	2
7	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Modern Pathology, 2021, 34, 1245-1260.	5.5	21
8	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. Clinical Neurology and Neurosurgery, 2021, 208, 106882.	1.4	1
9	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathology, 2020, 30, 541-553.	4.1	73
10	Radiomic Features From Multi-Parameter MRI Combined With Clinical Parameters Predict Molecular Subgroups in Patients With Medulloblastoma. Frontiers in Oncology, 2020, 10, 558162.	2.8	34
11	Clinical and mutational profiles of adult medulloblastoma groups. Acta Neuropathologica Communications, 2020, 8, 191.	5.2	30
12	Incremental prognostic value and underlying biological pathways of radiomics patterns in medulloblastoma. EBioMedicine, 2020, 61, 103093.	6.1	23
13	Molecular subgrouping of medulloblastoma based on few-shot learning of multitasking using conventional MR images: a retrospective multicenter study. Neuro-Oncology Advances, 2020, 2, vdaa079.	0.7	5
14	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro-Oncology Advances, 2019, 1, vdz015.	0.7	22
15	MEDU-05. PROGNOSTIC IMPLICATION OF TERT PROMOTER MUTATION AND TP53 NUCLEAR STAINING IN ADULT MEDULLOBLASTOMA. Neuro-Oncology, 2019, 21, ii104-ii104.	1.2	0
16	Wholeâ€exome sequencing revealed mutational profiles of giant cell glioblastomas. Brain Pathology, 2019, 29, 782-792.	4.1	11
17	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. Journal of Neuro-Oncology, 2018, 139, 307-322.	2.9	2
18	Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathologica, 2018, 136, 641-655.	7.7	36

#	Article	IF	Citations
19	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. Laboratory Investigation, 2017, 97, 946-961.	3.7	24
20	Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology, 2017, 19, 1327-1337.	1.2	177
21	An Unusual Combination of Mirror-Image Dextrocardia with Familial Medulloblastoma: Is There a Histogenetic Relationship?. World Neurosurgery, 2017, 107, 860-867.	1.3	0
22	Dual degradation signals destruct GLI1: AMPK inhibits GLI1 through Î²-TrCP-mediated proteasome degradation. Oncotarget, 2017, 8, 49869-49881.	1.8	20
23	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget, 2016, 7, 64615-64630.	1.8	22
24	Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation. Medical Oncology, 2016, 33, 99.	2.5	10
25	Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget, 2016, 7, 5030-5041.	1.8	45
26	Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget, 2015, 6, 20885-20901.	1.8	42
27	<scp>miR</scp>â€106b is overexpressed in medulloblastomas and interacts directly with <scp>PTEN</scp>. Neuropathology and Applied Neurobiology, 2015, 41, 145-164.	3.2	37
28	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Modern Pathology, 2015, 28, 177-186.	5.5	107
29	CRMP1 Inhibits Proliferation of Medulloblastoma and Is Regulated by HMGA1. PLoS ONE, 2015, 10, e0127910.	2.5	13
30	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Modern Pathology, 2014, 27, 332-342.	5.5	45
31	Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e99490.	2.5	24
32	<scp>MiR</scp>â€383 is Downregulated in Medulloblastoma and Targets Peroxiredoxin 3 (<scp>PRDX3</scp>). Brain Pathology, 2013, 23, 413-425.	4.1	71
33	<scp>MIR</scp>â€137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets <scp>CSE1L</scp>. Brain Pathology, 2013, 23, 426-439.	4.1	39
34	Signaling pathway and molecular subgroups of medulloblastoma. International Journal of Clinical and Experimental Pathology, 2013, 6, 1211-22.	0.5	18